| A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS (NCT07728097) | Jazz Pharmaceuticals | 2026-11-18 |
| A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE (NCT07723976) | Jazz Pharmaceuticals | 2026-10-30 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy (NCT07723963) | Jazz Pharmaceuticals | 2026-09-01 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC (NCT07459634) | Jazz Pharmaceuticals | 2026-08-30 |
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma (NCT07533942) | Jazz Pharmaceuticals | 2026-07-16 |
| A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH (NCT07625280) | Jazz Pharmaceuticals | 2026-06-30 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants (NCT07377539) | Jazz Pharmaceuticals | 2026-02-03 |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma (NCT07282587) | Jazz Pharmaceuticals | 2026-01-02 |
| A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures (NCT07233239) | Jazz Pharmaceuticals | 2025-11-26 |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (NCT07102381) | Jazz Pharmaceuticals | 2025-09-24 |
| Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy (NCT06113237) | Jazz Pharmaceuticals | 2025-08-05 |
| A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 (NCT06961266) | Jazz Pharmaceuticals | 2025-05-13 |
| Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY (NCT05485831) | Jazz Pharmaceuticals | 2025-02-24 |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors (NCT06695845) | Jazz Pharmaceuticals | 2025-01-14 |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer (NCT06435429) | Jazz Pharmaceuticals | 2024-08-13 |
| VYxeoS Liposomal Italian Observational Study iN the Real Practice (NCT06143839) | Jazz Pharmaceuticals | 2023-12-07 |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (NCT06108050) | Jazz Pharmaceuticals | 2023-11-07 |
| A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder (NCT05733390) | Jazz Pharmaceuticals | 2023-06-30 |
| A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex (NCT05864846) | Jazz Pharmaceuticals | 2023-06-29 |
| A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy (NCT05869773) | Jazz Pharmaceuticals | 2023-06-26 |
| Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting (NCT05772429) | Jazz Pharmaceuticals | 2023-04-17 |
| A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants (NCT05720494) | Jazz Pharmaceuticals | 2023-01-26 |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (NCT05580562) | Jazz Pharmaceuticals | 2023-01-23 |
| A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors (NCT05631327) | Jazz Pharmaceuticals | 2022-12-19 |
| A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease (NCT05642442) | Jazz Pharmaceuticals | 2022-12-01 |
| A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants (NCT05651152) | Jazz Pharmaceuticals | 2022-11-28 |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures (NCT05288283) | Jazz Pharmaceuticals | 2022-10-31 |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 (NCT05557045) | Jazz Pharmaceuticals | 2022-10-10 |
| Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (NCT05126433) | Jazz Pharmaceuticals | 2022-03-03 |
| CPX-351 Real-World Effectiveness and Safety Study (NCT05169307) | Jazz Pharmaceuticals | 2022-01-14 |
| A Study of JZP150 in Adults With Posttraumatic Stress Disorder (NCT05178316) | Jazz Pharmaceuticals | 2021-12-29 |
| A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) (NCT05122650) | Jazz Pharmaceuticals | 2021-12-06 |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (NCT05152147) | Jazz Pharmaceuticals | 2021-12-02 |
| A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer (NCT05027139) | Jazz Pharmaceuticals | 2021-09-15 |
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis (NCT04984278) | Jazz Pharmaceuticals | 2021-08-16 |
| Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution (NCT05044819) | Jazz Pharmaceuticals | 2021-07-07 |
| To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (NCT04894591) | Jazz Pharmaceuticals | 2021-06-28 |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures (NCT04485104) | Jazz Pharmaceuticals | 2021-05-19 |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (NCT04571645) | Jazz Pharmaceuticals | 2021-04-30 |
| A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy (NCT04803786) | Jazz Pharmaceuticals | 2021-04-09 |
| An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy (NCT04794491) | Jazz Pharmaceuticals | 2021-03-22 |
| Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder (NCT04592159) | Jazz Pharmaceuticals | 2021-02-01 |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis (NCT04657666) | Jazz Pharmaceuticals | 2020-12-21 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (NCT04541082) | Jazz Pharmaceuticals | 2020-10-26 |
| Child and Adolescent Registry for Participants With Narcolepsy (NCT04899947) | Jazz Pharmaceuticals | 2020-10-10 |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis (NCT04203498) | Jazz Pharmaceuticals | 2020-10-01 |
| Investigation of Cognitive Outcomes With Cannabidiol Oral Solution (NCT04133480) | Jazz Pharmaceuticals | 2020-10-01 |
| A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (NCT04466891) | Jazz Pharmaceuticals | 2020-10-01 |
| Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment (NCT04421456) | Jazz Pharmaceuticals | 2020-08-18 |
| Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure (NCT04389840) | Jazz Pharmaceuticals | 2020-07-08 |
| A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer (NCT04224272) | Jazz Pharmaceuticals | 2020-06-10 |
| A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (NCT04252586) | Jazz Pharmaceuticals | 2020-02-28 |
| Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder (NCT03849456) | Jazz Pharmaceuticals | 2020-01-07 |
| An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) (NCT04145531) | Jazz Pharmaceuticals | 2019-12-27 |
| A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease (NCT03436953) | Jazz Pharmaceuticals | 2019-12-01 |
| A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML (NCT04038437) | Jazz Pharmaceuticals | 2019-10-15 |
| A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity (NCT03954106) | Jazz Pharmaceuticals | 2019-10-04 |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (NCT03929666) | Jazz Pharmaceuticals | 2019-08-29 |
| Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (NCT03848832) | Jazz Pharmaceuticals | 2019-07-29 |
| A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension (NCT03533114) | Jazz Pharmaceuticals | 2018-11-27 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (NCT03555955) | Jazz Pharmaceuticals | 2018-11-20 |
| A Post-Marketing Observational Study of VYXEOS™ (NCT03526926) | Jazz Pharmaceuticals | 2018-10-23 |
| ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer (NCT03485729) | Jazz Pharmaceuticals | 2018-03-21 |
| CX-8998 for Absence Seizures (NCT03406702) | Jazz Pharmaceuticals | 2018-02-25 |
| An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) (NCT03339297) | Jazz Pharmaceuticals | 2018-02-21 |
| ONC201 in Pediatric H3 K27M Gliomas (NCT03416530) | Jazz Pharmaceuticals | 2018-01-25 |
| The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation (NCT03339401) | Jazz Pharmaceuticals | 2017-12-22 |